SunRISe Study for Janssen
Services Provided: Branding, Logo Design, Data Visualization, Print Collat
Introduction
The SunRISe study was a Phase 2 clinical trial designed to evaluate the efficacy and safety of TAR-200 in combination with cetrelimab for treating muscle-invasive bladder cancer. The design approach focused on inclusivity and accessibility, ensuring that information was clear and comprehensive to support patients throughout their individual clinical trial journey.
Project Objectives
Create Cohesive Branding: Develop a unified visual identity for the study that reflects Janssen's commitment to innovation and excellence in clinical research.
Support Study Execution: Design materials that facilitate the recruitment process, patient understanding, and regulatory compliance.
Logo + Branding Development
Consistency
Established a consistent visual identity across all materials to ensure brand recognition and cohesion. This included the integration of the SunRISe logo, color palette, and typography into every asset, from brochures to digital presentations.
Accessibility
Materials were designed with a focus on readability and accessibility, ensuring that information is easily understood by a diverse patient population. This includes the use of simple language, clear layouts, and visual aids.
Results
Enhanced Engagement
The patient brochure and informed consent flipchart facilitated a better understanding of the study’s purpose, processes, and risks, leading to smoother recruitment and informed participation.
Efficient Study Execution
The study binders and informational flowcharts improved organization and clarity, supporting effective management of the trial and compliance with regulatory requirements.
Impact
The branding and materials for the SunRISe Study successfully supported the trial’s objectives by enhancing visibility, improving patient engagement, and ensuring consistent communication across all stakeholders.
